Significantly, ZEB2 blockade could reverse the polarization of TAMs both in vitro and in vivo, which may contribute to rendering the immunosuppressive trend of the transformation of TME in EGFR-TKI-resistant NSCLC, serving as a potential target for therapeutic intervention synergistic to ICI therapy. Here, ZEB2 is linked to non-small cell lung carcinoma.